Augmented muscarinic responsiveness caused by 5-lipoxygenase products secreted from alveolar macrophages in isolated-perfused rat lung.
We examined the effect of activated alveolar macrophages (AM) on airway responsiveness to muscarinic stimulation in 33 adult Sprague-Dawley rats. An isolated-perfused lung preparation was used to ensure precise and uniform delivery of cells into peripheral airways. The bronchoconstrictor response to acetylcholine (ACh) delivered into the pulmonary arterial circulation was augmented in 8 rats after infusion of 3 x 10(6) AM activated with 10(-6) M f-met-leu-phe and 5 micrograms/ml of cytochalasin B. Lung resistance (RL) caused by 10(-6) mol ACh increased 2.5-fold from 0.10 +/- 0.004 cm H2O/ml/s before infusion of activated AM to 0.35 +/- 0.05 cm H2O/ml/s after infusion of activated AM (N = 8; p < 0.05); the response to ACh was not augmented after infusion of nonactivated AM (N = 7) or vehicle control (N = 6). Baseline RL before ACh was similar in all three groups (p NS). Perfusion with activated AM also significantly increased the wet/dry (W/D) lung weight ratios (7.1 +/- 0.5) compared with nonactivated AM (5.2 +/- 0.1) or vehicle control (5.5 +/- 0.3) (p < 0.05 versus either nonactivated AM or vehicle control). A63162, a 5-lipoxygenase inhibitor, but not indomethacin, a cyclooxygenase inhibitor, completely inhibited augmentation of bronchoconstrictor responses to ACh caused by activated AM and also completely attenuated the increase in W/D lung weight ratios. A highly significant (p < 0.01) correlation (R = 0.76) between W/D lung weight ratios and RL was observed after 10(-6) mol ACh (the greatest dose of ACh administered). Baseline RL was equivalent for all groups before and after infusion of cells or vehicle.(ABSTRACT TRUNCATED AT 250 WORDS)
Department of Medicine, University of Chicago, IL 60637.
P
P
Padrid
R
R
Wolf
N M
NM
Munoz
S
S
Spaethe
T
T
Finucane
J
J
Solway
A R
AR
Leff
D000109:Acetylcholine / Q000494:pharmacology; D000403:Airway Resistance; D000704:Analysis of Variance; D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism / Q000494:pharmacology*; D016535:Bronchial Hyperreactivity / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D002648:Child; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007223:Infant; D016018:Least-Squares Analysis; D016859:Lipoxygenase Inhibitors; D008168:Lung / Q000187:drug effects* / Q000503:physiopathology; D008262:Macrophage Activation; D016676:Macrophages, Alveolar / Q000201:enzymology* / Q000378:metabolism; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010477:Perfusion / Q000379:methods; D011897:Random Allocation; D051381:Rats; D011976:Receptors, Muscarinic / Q000187:drug effects* / Q000502:physiology
D016859:Lipoxygenase Inhibitors; D011976:Receptors, Muscarinic; D001094:Arachidonate 5-Lipoxygenase; D000109:Acetylcholine